ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 366,92
-0,86%
Dow Jones
41 938,45
-1,63%
DAX
20 058,48
-0,81%
Brent Oil
80,455
-0,20%
Bitcoin
90 713,16
-4,01%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Organovo Holdings Inc (ONVO)

  7. Organovo Holdings Inc (ONVO) Actualités

ONVO

Organovo (ONVO)

Organovo Holdings Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ONVO
DateHeureSourceTitreSymboleSociété
08/01/202522h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ONVOOrganovo Holdings Inc
31/12/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ONVOOrganovo Holdings Inc
20/11/202414h05GlobeNewswire Inc.Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver MeetingNASDAQ:ONVOOrganovo Holdings Inc
14/11/202421h34Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ONVOOrganovo Holdings Inc
13/11/202414h06GlobeNewswire Inc.Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver DiseasesNASDAQ:ONVOOrganovo Holdings Inc
08/11/202422h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ONVOOrganovo Holdings Inc
25/10/202423h00Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ONVOOrganovo Holdings Inc
18/09/202422h05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ONVOOrganovo Holdings Inc
09/08/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ONVOOrganovo Holdings Inc
26/07/202422h05Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ONVOOrganovo Holdings Inc
16/07/202414h05GlobeNewswire Inc.Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative ColitisNASDAQ:ONVOOrganovo Holdings Inc
31/05/202422h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ONVOOrganovo Holdings Inc
21/05/202414h05GlobeNewswire Inc.Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel DiseaseNASDAQ:ONVOOrganovo Holdings Inc
14/05/202418h45Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ONVOOrganovo Holdings Inc
14/05/202417h00GlobeNewswire Inc.Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)NASDAQ:ONVOOrganovo Holdings Inc
09/05/202402h00GlobeNewswire Inc.Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public OfferingNASDAQ:ONVOOrganovo Holdings Inc
15/04/202414h05GlobeNewswire Inc.Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to PlaceboNASDAQ:ONVOOrganovo Holdings Inc
09/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ONVOOrganovo Holdings Inc
08/02/202422h56Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ONVOOrganovo Holdings Inc
26/01/202423h09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ONVOOrganovo Holdings Inc
25/01/202414h05GlobeNewswire Inc.Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis CongressNASDAQ:ONVOOrganovo Holdings Inc
09/01/202414h05GlobeNewswire Inc.Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis CongressNASDAQ:ONVOOrganovo Holdings Inc
06/12/202314h05GlobeNewswire Inc.Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsNASDAQ:ONVOOrganovo Holdings Inc
01/12/202322h07Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ONVOOrganovo Holdings Inc
15/11/202322h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ONVOOrganovo Holdings Inc
13/11/202314h05GlobeNewswire Inc.CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanNASDAQ:ONVOOrganovo Holdings Inc
08/11/202314h05GlobeNewswire Inc.Organovo Highlights FXR314 Combination Therapy Potential and PlanNASDAQ:ONVOOrganovo Holdings Inc
22/09/202322h05Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ONVOOrganovo Holdings Inc
13/09/202323h07Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ONVOOrganovo Holdings Inc
13/09/202323h06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ONVOOrganovo Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ONVO

Dernières Valeurs Consultées

BIT
NSCIT0541549
Republic of Italy
BIT
UC6TH5
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés